KR101697914B1 - 그라피프란트의 결정형 - Google Patents

그라피프란트의 결정형 Download PDF

Info

Publication number
KR101697914B1
KR101697914B1 KR1020167024256A KR20167024256A KR101697914B1 KR 101697914 B1 KR101697914 B1 KR 101697914B1 KR 1020167024256 A KR1020167024256 A KR 1020167024256A KR 20167024256 A KR20167024256 A KR 20167024256A KR 101697914 B1 KR101697914 B1 KR 101697914B1
Authority
KR
South Korea
Prior art keywords
crystalline
theta
shows
exhibits
exothermic
Prior art date
Application number
KR1020167024256A
Other languages
English (en)
Korean (ko)
Other versions
KR20160106779A (ko
Inventor
타마라 뉴볼드
멜리사 스미스
크리스 시캄프
로버트 웬슬로우
시아 루
Original Assignee
아라타나 세라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아라타나 세라퓨틱스, 인크. filed Critical 아라타나 세라퓨틱스, 인크.
Publication of KR20160106779A publication Critical patent/KR20160106779A/ko
Application granted granted Critical
Publication of KR101697914B1 publication Critical patent/KR101697914B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Led Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ceramic Products (AREA)
  • Inorganic Insulating Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
KR1020167024256A 2014-03-06 2015-03-05 그라피프란트의 결정형 KR101697914B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461949006P 2014-03-06 2014-03-06
US61/949,006 2014-03-06
US201461996961P 2014-07-30 2014-07-30
US61/996,961 2014-07-30
PCT/US2015/019043 WO2015134797A1 (en) 2014-03-06 2015-03-05 Crystalline forms of grapiprant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000896A Division KR101771385B1 (ko) 2014-03-06 2015-03-05 그라피프란트의 결정형

Publications (2)

Publication Number Publication Date
KR20160106779A KR20160106779A (ko) 2016-09-12
KR101697914B1 true KR101697914B1 (ko) 2017-01-18

Family

ID=54016295

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167024256A KR101697914B1 (ko) 2014-03-06 2015-03-05 그라피프란트의 결정형
KR1020177000896A KR101771385B1 (ko) 2014-03-06 2015-03-05 그라피프란트의 결정형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177000896A KR101771385B1 (ko) 2014-03-06 2015-03-05 그라피프란트의 결정형

Country Status (16)

Country Link
US (1) US9265756B2 (zh)
EP (4) EP3520790A1 (zh)
JP (2) JP6535683B2 (zh)
KR (2) KR101697914B1 (zh)
CN (11) CN107573339A (zh)
AU (1) AU2015227064B2 (zh)
CA (10) CA2997703A1 (zh)
DK (3) DK3511000T3 (zh)
ES (3) ES2816057T3 (zh)
MX (1) MX367376B (zh)
NZ (3) NZ733225A (zh)
PL (3) PL3113773T3 (zh)
PT (3) PT3295941T (zh)
RU (1) RU2638931C1 (zh)
TW (1) TWI537270B (zh)
WO (1) WO2015134797A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105939713A (zh) 2014-03-06 2016-09-14 阿莱塔纳治疗学股份有限公司 格拉匹纶组合物及其使用方法
CA3096546A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
WO2020014465A1 (en) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US11254675B2 (en) 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018158A1 (en) * 2005-03-11 2009-01-15 Naoaki Haruta Crystal forms of an imidazole derivative
US20110136887A1 (en) 2008-08-14 2011-06-09 Beta Pharma Canada Inc. Heterocyclic Amide Derivatives as EP4 Receptor Antagonists
US20130261185A1 (en) 2006-12-15 2013-10-03 Glaxo Group Limited Benzamide Derivatives As EP4 Receptor Agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
KR101368519B1 (ko) * 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
BR112013029319A2 (pt) 2011-05-18 2017-01-31 Raqualia Pharma Inc forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018158A1 (en) * 2005-03-11 2009-01-15 Naoaki Haruta Crystal forms of an imidazole derivative
US20130261185A1 (en) 2006-12-15 2013-10-03 Glaxo Group Limited Benzamide Derivatives As EP4 Receptor Agonists
US20110136887A1 (en) 2008-08-14 2011-06-09 Beta Pharma Canada Inc. Heterocyclic Amide Derivatives as EP4 Receptor Antagonists

Also Published As

Publication number Publication date
JP6535683B2 (ja) 2019-06-26
PL3295941T3 (pl) 2020-11-16
DK3295941T3 (da) 2020-08-24
PT3295941T (pt) 2020-08-25
CN107540671A (zh) 2018-01-05
CA2997694C (en) 2021-04-06
EP3113773A4 (en) 2017-05-10
ES2755396T3 (es) 2020-04-22
CN107573339A (zh) 2018-01-12
CN107501263A (zh) 2017-12-22
DK3511000T3 (da) 2022-05-30
EP3295941A1 (en) 2018-03-21
CN107759589A (zh) 2018-03-06
CA2997692A1 (en) 2015-09-11
EP3511000B1 (en) 2022-04-27
CA3105571A1 (en) 2015-09-11
PL3511000T3 (pl) 2022-08-22
CN110256426A (zh) 2019-09-20
CA2997694A1 (en) 2015-09-11
MX2016011023A (es) 2016-11-28
KR20160106779A (ko) 2016-09-12
JP2018065819A (ja) 2018-04-26
CN107759591A (zh) 2018-03-06
NZ733234A (en) 2018-08-31
CN107759590A (zh) 2018-03-06
CA2997741A1 (en) 2015-09-11
EP3295941B1 (en) 2020-07-22
CA2997718A1 (en) 2015-09-11
AU2015227064B2 (en) 2017-05-11
KR101771385B1 (ko) 2017-08-24
CA2941019A1 (en) 2015-09-11
CN113087705A (zh) 2021-07-09
EP3113773B1 (en) 2019-09-18
PT3511000T (pt) 2022-05-25
CN107400132A (zh) 2017-11-28
TWI537270B (zh) 2016-06-11
CN105764508A (zh) 2016-07-13
KR20170008889A (ko) 2017-01-24
NZ724923A (en) 2018-03-23
JP2017507161A (ja) 2017-03-16
EP3511000A1 (en) 2019-07-17
PT3113773T (pt) 2019-11-12
EP3520790A1 (en) 2019-08-07
MX367376B (es) 2019-08-16
CA3168877A1 (en) 2015-09-11
PL3113773T3 (pl) 2020-05-18
CA2997703A1 (en) 2015-09-11
WO2015134797A1 (en) 2015-09-11
NZ733225A (en) 2018-03-23
EP3113773A1 (en) 2017-01-11
AU2015227064A1 (en) 2016-10-27
US20150250774A1 (en) 2015-09-10
CN107501262A (zh) 2017-12-22
CA2997746A1 (en) 2015-09-11
ES2919346T3 (es) 2022-07-26
RU2638931C1 (ru) 2017-12-19
TW201538500A (zh) 2015-10-16
US9265756B2 (en) 2016-02-23
CA2997697A1 (en) 2015-09-11
ES2816057T3 (es) 2021-03-31
DK3113773T3 (da) 2019-11-18

Similar Documents

Publication Publication Date Title
KR101697914B1 (ko) 그라피프란트의 결정형
WO2010027770A1 (en) Crystalline forms of sufentanil citrate
US8227483B2 (en) Polymorphs of 6-beta-naltrexol

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant